English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Prion diseases are associated with the conformational conversion of the physiological form of cellular prion protein (PrP C ) to the pathogenic form, PrP Sc . Compounds that inhibit this process by blocking conversion to the PrP Sc  could provide useful anti-prion therapies. However, no suitable drugs have been identified to date. To identify novel anti-prion compounds, we developed a combined structure- and ligand-based virtual screening system  in silico . Virtual screening of a 700,000-compound database, followed by cluster analysis, identified 37 compounds with strong interactions with essential hotspot PrP residues identified in a previous study of PrP C  interaction with a known anti-prion compound (GN8). These compounds were tested  in vitro  using a multimer detection system, cell-based assays, and surface plasmon resonance. Some compounds effectively reduced PrP Sc  levels and one of these compounds also showed a high binding affinity for PrP C . These results provide a promising starting point for the development of anti-prion compounds.

Discovery of Novel Anti-prion Compounds Using In Silico and In Vitro Approaches